Navigation Links
Rapid and Long-term Clinical Responses Observed in Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol), According to Data Being Highlighted During ACR Meeting
Date:11/5/2010

ATLANTA, Nov. 5, 2010 /PRNewswire/ -- Cimzia® (certolizumab pegol) data demonstrating rapid and sustained improvements in managing moderate to severe rheumatoid arthritis (RA) symptoms, reducing disease activity and inhibiting joint damage progression will be exhibited during the American College of Rheumatology's 2010 Annual Scientific Meeting in Atlanta, November 7-11.

Cimzia is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis.

Following is a guide to Cimzia posters and other UCB-sponsored research being exhibited during ACR:

  • Efficacy and Safety of Certolizumab Pegol in a Clinically Representative Population of Patients (Pts) With Active Rheumatoid Arthritis (RA): Results of the REALISTIC Phase IIIb Randomized Controlled Study
  • In a diverse group of RA patients reflecting those seen in daily clinical practice (including those with prior TNF-inhibitor use), addition of CZP to current therapy was associated with a rapid clinical response, improved function and reduced disease activity with a favorable risk benefit profile.  For full study information, please see: http://www.abstracts2view.com/acr/titleindex.php?num=E&page=2
  • 1805 - Wednesday, November 10, 2010, 9:00 am
  • Halls B1 & B2, APS - ACR/ARHP Poster Session C

  • Efficacy and Safety of Certolizumab Pegol Plus Methotrexate in Patients With Rheumatoid Arthritis (RA): 3-Year Data From the RAPID 2 Study
  • In patients with active RA despite methotrexate treatment, the addition of CZP provides clinical improvements that were sustained over 3 years, inhibits joint damage progression, and was shown to be well tolerated.  For full study information, please see: http://www.abstracts2view.com/acr/titleindex.php?nu
    '/>"/>

  • SOURCE UCB
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related medicine technology :

    1. Biosimilar Erosion of Branded ESA Market Share Will be More Rapid in the U.S. Than in Europe
    2. Results of Boehringer Ingelheim Oral Hepatitis C Protease Inhibitor and Polymerase Inhibitor Combination Phase Ib Trial Shows Rapid Viral Response Without Use of Pegylated Interferon
    3. Installation of Next Generation Proton Therapy System Progressing Rapidly
    4. endpoint Launches PULSE 2.0 Allowing Clinical Research Teams to Save Additional Time and Money By Rapidly Deploying Studies With Custom Reporting
    5. Radiation Oncology Expert From Stanford University Highlights How Image Guidance and RapidArc® Technology are Improving the Treatment of Lung Cancer
    6. Sagent Pharmaceuticals Announces Launch of ANEclear Device for Rapid Clearance of Inhaled Anesthetics Following Surgery
    7. New Institute Paves Way for Rapid Cancer Drug Development
    8. Chongqing Cancer Hospital Becomes First Hospital in Southwest China to Offer Cancer Patients Fast, Precise Treatment Using RapidArc® Radiotherapy from Varian Medical Systems
    9. Medco Completes Acquisition of United BioSource Corporation, Creating Powerful Engine for Rapidly Advancing Clinical Insight and Innovation
    10. Swiss Breast Cancer Patient Becomes First in World to Receive Treatment Using Gated RapidArc from Varian Medical Systems
    11. Cancer Patients in Scotland Gain Access to Advanced RapidArc Radiotherapy Treatments from Varian Medical Systems
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/22/2014)... , Aug. 22, 2014  WaferGen Bio-systems, Inc. ... public offering of units of common stock and warrants ... proceeds of $20 million, prior to deducting underwriting discounts ... The shares and warrants are immediately separable and will ... expected to begin trading on The NASDAQ Stock Market ...
    (Date:8/21/2014)... Nektar Therapeutics (NASDAQ: NKTR ... results from its Phase 3 pivotal clinical trial ... factor VIII (rFVIII) treatment for hemophilia A based ... primary endpoint in reducing annualized bleed rates (ABR) ... arm. Top-line results from the prospective, ...
    (Date:8/21/2014)... /CNW/ - Eisai Limited is pleased to support the Canadian ... book available in Canada . The comic ... educate children and their parents about epilepsy, the most common ... than 300,000 Canadians. Eisai is guided by a corporate philosophy ... the patient is central – there was a need within ...
    Breaking Medicine Technology:WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2
    ... , June 14 Upsher-Smith Laboratories, Inc. today ... for USL255 (extended-release topiramate), an internally developed program for the ... technology.  USL255 is designed to provide convenient once-daily dosing and ... topiramate options. , , ...
    ... /PRNewswire/ -- MedShape Solutions, Inc. was recently ... for their MORPHIX™ Suture Anchor at the recent Medical ... of jurors awarded the MORPHIX™ Anchor the Gold Award ... proprietary shape memory polymer, PEEK Altera™.  Previous winners of ...
    Cached Medicine Technology:Upsher-Smith Laboratories Announces Initiation of Phase III Clinical Trial of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy 2Upsher-Smith Laboratories Announces Initiation of Phase III Clinical Trial of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy 3MedShape Solutions, Inc. Receives Industry Honors and Awards 2
    (Date:8/23/2014)... August 23, 2014 The report ... Trends & Forecasts to 2018” defines and segments ... forecasting of the global revenue and consumption. It ... global polycarbonate resin market with analysis of trends, ... segmented, and consumption and revenues are forecasted on ...
    (Date:8/23/2014)... According to the new research ... and Geography - Regional Trends & Forecast to ... with an analysis and forecast of value individually. ... electronic adhesives by applications and geography are also ... data tables and 26 figures spread through 234 ...
    (Date:8/23/2014)... A team of New York researchers say ... preceded by surgery and delivered by an experienced team. Surviving ... Click here to read it now . , ... of mesothelioma patients who underwent hemithoracic (one side of ... the shape of a tumor. Patients who had surgery ...
    (Date:8/23/2014)... On Monday, August 18th, The New ... suffered by Community Health Systems, which operates over 200 ... records containing Personally Identifiable Information (PII) like names, phone ... was engaged to investigate the incident, the belief is ... cyber attackers based in China, who they say are ...
    (Date:8/23/2014)... Boston, MA (PRWEB) August 23, 2014 ... now have a study aid in preparing for Food ... safety practice test by Dynamic Path. , Dynamic ... study module, which includes more than 200 review questions ... study materials are designed to cover requirements of the ...
    Breaking Medicine News(10 mins):Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 2Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 3Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 4Health News:Electronic Adhesives Market Poised to Reach $5.5 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Electronic Adhesives Market Poised to Reach $5.5 Billion by 2019 - New Report by MarketsandMarkets 3Health News:New Study Links Hospital Experience and Prior Surgery with Mesothelioma Radiation Success, According to Surviving Mesothelioma 2Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 2Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 3Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 4Health News:Food Handler Safety Certification Made Easy with Dynamic Path 2
    ... VIRGINIA BEACH, Va., Jan. 11, 2010 Amerigroup Corporation (NYSE: ... for the fourth quarter and the fiscal year ended December 31, ... 2010. At 8:30 a.m. Eastern Time on the same day, ... earnings and other information. , To listen to the call, dial ...
    ... Urges Legislators Not to Balance Budget on Backs of Elderly & Work ... Jim Wordelman AARP State Director for Idaho , BOISE, Idaho, Jan. ... out a broad road map for Idaho in the coming year - ... commitment of bring more doctors to Idaho to perform their residencies is ...
    ... MAYWOOD, Il. -- A 21-gene test that predicts whether early ... a big impact on treatment decisions by patients and doctors ... recommendations in 31.5 percent of cases, while 27 percent of ... the change by both doctors and patients was to avoid ...
    ... Free ... and Austin, Texas areas. , ... San Antonio, TX (PRWEB) January 11, 2010 -- Physicians Health Choice -- ... benefits than original Medicare -- is pleased to announce it is partnering with Silver ...
    ... , , BATESVILLE, Ind., ... hosting an investor luncheon from noon to 1:30 p.m. in New York, ... 2010, to discuss the definitive agreement for Hillenbrand to acquire K-Tron International, ... luncheons will provide an opportunity to hear from and meet members of ...
    ... WebMD Health Corp. (Nasdaq: WBMD ) today announced that executives ... Growth Stock Conference on Thursday, January 14, 2010 at 11:20 a.m. ... invited to listen to a live audio broadcast of the presentation ... www.wbmd.com (in the Investor Relations section). A replay of the ...
    Cached Medicine News:Health News:Amerigroup Corporation to Discuss Fourth Quarter and 2009 Year-End Earnings on February 19 2Health News:Idaho State of the State Holds Promise & Problems 2Health News:Breast cancer multigene test helping patients avoid chemotherapy 2Health News:Top-Rated Medicare Plan Now Offers Silver Life Fitness Program Free to its Members 2Health News:Top-Rated Medicare Plan Now Offers Silver Life Fitness Program Free to its Members 3Health News:Hillenbrand to Host Investor Luncheons in New York City and Boston 2Health News:Hillenbrand to Host Investor Luncheons in New York City and Boston 3Health News:Hillenbrand to Host Investor Luncheons in New York City and Boston 4Health News:Hillenbrand to Host Investor Luncheons in New York City and Boston 5
    ENDO STITCH™ Single Use Loading Units....
    ... single use suturing device has application ... of interrupted or running stitches in ... use suturing device is available in ... with the choice of 4 suture ...
    ... Suture Assistant is a sterile, single-patient-use instrument ... and in placing a suture and a ... button to tie a secure intracorporeal knot., ... the ENDOPATH 5mm trocars or larger trocars ...
    ... 42" long suture inserted into a plastic tube. ... and scored on the other. The suture protrudes ... ST-3 needle. The opposite end of the suture ... plastic tube. The scored end acts as the ...
    Medicine Products: